{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:22:14Z","timestamp":1791843734226,"version":"4.3.4"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Pediatric multiple sclerosis (MS) is rare: only 1.5\u20135% of MS cases are diagnosed before 18 years of age, and data on disease-modifying therapies (DMTs) for pediatric MS are limited. The CONNECTED study assessed the long-term safety and efficacy of treatment with delayed-release dimethyl fumarate (DMF), an oral MS DMT, in pediatric patients with MS.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> CONNECTED is the 96-week extension to FOCUS, a 24-week phase 2 study of patients aged 13\u201317 years; participants received DMF 240 mg twice daily. Endpoints included (primary) incidence of adverse events (AEs), serious AEs, and DMF discontinuations due to an AE, and (secondary) T2 hyperintense lesion incidence by magnetic resonance imaging and annualized relapse rate (ARR).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Twenty participants [median (range) age, 17 (14\u201318) years; 65% female] who completed FOCUS enrolled into CONNECTED; 17 (85%) completed CONNECTED. Eighteen participants (90%) experienced AEs: the most frequent was flushing (25%). None experienced infections or fever related to low lymphocyte counts. Three participants experienced four serious AEs; none led to DMF discontinuation. Twelve of 17 participants (71%) had no new\/newly enlarged T2 lesions from weeks 16\u201324, two (12%) had one, and one each (6%) had two, three, or five or more lesions [median (range), 0 (0\u20136)]. Over the full 120-week treatment period, ARR was 0.2, an 84.5% relative reduction (<jats:italic>n<\/jats:italic> = 20; 95% confidence interval: 66.8\u201392.8; <jats:italic>p<\/jats:italic> &amp;lt; 0.0001) vs. the year before DMF initiation.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> The long-term safety and efficacy observed in CONNECTED was consistent with adults, suggesting pediatric and adolescent patients with MS might benefit from DMF treatment.<\/jats:p>","DOI":"10.3389\/fneur.2020.606418","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T15:17:01Z","timestamp":1609773421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Raed","family":"Alroughani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Huppke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mazurkiewicz-Beldzinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Blaschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Valis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Aaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Pultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Beynon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/jnnp-2012-303996","article-title":"Long-term outcome of paediatric-onset multiple sclerosis: a population-based study","volume":"84","author":"Harding","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/135245859700300105","article-title":"Multiple sclerosis in childhood: clinical features of 149 cases","volume":"3","author":"Ghezzi","year":"1997","journal-title":"Mult Scler."},{"key":"B4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/1352458508101933","article-title":"Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States","volume":"15","author":"Chitnis","year":"2009","journal-title":"Mult Scler."},{"key":"B5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1474-4422(14)70093-6","article-title":"Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research","volume":"13","author":"Waldman","year":"2014","journal-title":"Lancet Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0022-3476(87)80454-7","article-title":"Multiple sclerosis in childhood: clinical profile in 125 patients","volume":"111","author":"Duquette","year":"1987","journal-title":"J Pediatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.59.7.1006","article-title":"Early onset multiple sclerosis: a longitudinal study","volume":"59","author":"Boiko","year":"2002","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1600-0404.1992.tb05086.x","article-title":"Early onset MS under the age of 16: clinical and paraclinical features","volume":"86","author":"Sindern","year":"1992","journal-title":"Acta Neurol Scand."},{"key":"B9","unstructured":"Atlas of MS 2013: Mapping Multiple Sclerosis Around the World.2013"},{"key":"B10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","article-title":"Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years","volume":"3","author":"Benson","year":"2014","journal-title":"Mult Scler Relat Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/archneurol.2008.505","article-title":"Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101511","DOI":"10.1016\/j.msard.2019.101511","article-title":"Factors associated with health care utilization in pediatric multiple sclerosis","volume":"38","author":"Marrie","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1212\/01.wnl.0000259407.40023.ab","article-title":"Treatment of pediatric multiple sclerosis and variants","volume":"68","author":"Pohl","year":"2007","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1177\/1352458510375568","article-title":"The management of multiple sclerosis in children: a European view","volume":"16","author":"Ghezzi","year":"2010","journal-title":"Mult Scler."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2538","DOI":"10.1212\/WNL.0000000000007572","article-title":"Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG","volume":"92","author":"Waubant","year":"2019","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1212\/WNL.0000000000002823","article-title":"Pediatric multiple sclerosis: conventional first-line treatment and general management","volume":"87","author":"Ghezzi","year":"2016","journal-title":"Neurology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11940-016-0420-7","article-title":"Use of disease-modifying therapies in pediatric MS","volume":"18","author":"Simone","year":"2016","journal-title":"Curr Treat Options Neurol."},{"key":"B18","unstructured":"Assessment Report. Rebif: International Non-proprietary Name: INTERFERON BETA-1A2013"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1212\/WNL.0000000000002884","article-title":"Pediatric multiple sclerosis: escalation and emerging treatments","volume":"87","author":"Chitnis","year":"2016","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12883-015-0433-y","article-title":"Natalizumab in the pediatric MS population: results of the Italian registry","volume":"15","author":"Ghezzi","year":"2015","journal-title":"BMC Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/PHMT.S220817","article-title":"Review of the safety, efficacy and tolerability of fingolimod in the treatment of pediatric patients with relapsing-remitting forms of multiple sclerosis (RRMS)","volume":"10","author":"Feng","year":"2019","journal-title":"Pediatr Health Med Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12883-018-1220-3","article-title":"A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries","volume":"19","author":"Saida","year":"2019","journal-title":"BMC Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1352458516649037","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study","volume":"23","author":"Gold","year":"2017","journal-title":"Mult Scler."},{"key":"B28","volume-title":"Data on File","year":"2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1124\/dmd.109.028209","article-title":"Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver","volume":"37","author":"Zhu","year":"2009","journal-title":"Drug Metab Dispos."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2016.01.010","article-title":"Oral dimethyl fumarate in children with multiple sclerosis: a dual-center study","volume":"57","author":"Makhani","year":"2016","journal-title":"Pediatr Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2018.03.007","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS)","volume":"83","author":"Alroughani","year":"2018","journal-title":"Pediatr Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler."},{"key":"B34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol Clin Pract."},{"key":"B35","doi-asserted-by":"publisher","first-page":"101871","DOI":"10.1016\/j.msard.2019.101871","article-title":"Clinical predictors of dimethyl fumarate response in multiple sclerosis: a real life multicentre study","volume":"38","author":"Lanzillo","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1756286420915005","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther Adv Neurol Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40120-019-0127-2","article-title":"Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes","volume":"8","author":"Min","year":"2019","journal-title":"Neurol Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e2764","DOI":"10.1212\/WNL.0000000000007647","article-title":"Long-term disability progression of pediatric-onset multiple sclerosis","volume":"92","author":"McKay","year":"2019","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1212\/WNL.0000000000002821","article-title":"Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases","volume":"87","author":"Bar-Or","year":"2016","journal-title":"Neurology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ana.21244","article-title":"Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes","volume":"63","author":"Banwell","year":"2008","journal-title":"Ann Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.4049\/jimmunol.0801888","article-title":"Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis","volume":"183","author":"McLaughlin","year":"2009","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/1352458513519181","article-title":"The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis","volume":"20","author":"Bove","year":"2014","journal-title":"Mult Scler."},{"key":"B43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/archneurol.2009.135","article-title":"Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults","volume":"66","author":"Waubant","year":"2009","journal-title":"Arch Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1352458517732843","article-title":"Therapy of highly active pediatric multiple sclerosis","volume":"25","author":"Huppke","year":"2019","journal-title":"Mult Scler."},{"key":"B45","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1212\/WNL.0000000000002880","article-title":"International Pediatric MS Study Group Global Members Symposium report","volume":"87","author":"Wassmer","year":"2016","journal-title":"Neurology."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaneurol.2019.1546","article-title":"Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis","volume":"76","author":"McKay","year":"2019","journal-title":"JAMA Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"18074","DOI":"10.1038\/s41598-019-54153-7","article-title":"Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis","volume":"9","author":"Carotenuto","year":"2019","journal-title":"Sci Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ejpn.2019.08.007","article-title":"Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis","volume":"23","author":"Johnen","year":"2019","journal-title":"Eur J Paediatr Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/jnnp-2019-321124","article-title":"Consistent control of disease activity with fingolimod versus IFN \u03b2-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS","volume":"91","author":"Deiva","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.606418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T15:17:08Z","timestamp":1609773428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.606418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":49,"alternative-id":["10.3389\/fneur.2020.606418"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.606418","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"article-number":"606418"}}